Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 15,200

Document Document Title
WO/2017/036992A1
The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions,such as a medicament, dietary supplement, functio...  
WO/2017/038645A1
The present embodiment provides a material is for forming underlayer films for lithography and contains a compound represented by formula (1) and/or a resin including a structural unit derived from the compound represented by formula (1)...  
WO/2017/036993A1
The invention provides compositions comprising a source of protein and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional foo...  
WO/2017/040836A1
A waterless decarboxylation device used to decarboxylate cannabis is described. For example, the device could include a product container to contain an amount of raw cannabis plant material, a heating container configured to surround and...  
WO/2017/036377A1
The invention relates to a near-infrared fluorescent dye and application thereof, and particularly relates to compounds represented by following formulas A, B and C, wherein each group in the formulas is described in the specification. F...  
WO/2017/032442A1
The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for ophthalmic devices as well as to ophthalmic devices comprising such compounds.  
WO/2017/032444A1
The present invention relates to novel compounds, particularly to hydrophilic compounds, comprising a photoactive unit, said novel compounds being particularly suitable for ophthalmic devices. The present application also relates to opht...  
WO/2017/032443A1
The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for ophthalmic devices as well as to ophthalmic devices comprising such compounds.  
WO/2017/032881A1
The present invention relates to compounds of formula (III) or to compounds of formula (IV) wherein R1, R2, R3 and R4 are as defined in the claims, and their use in therapeutic treatments of 5-lipoxygenase related diseases such as chroni...  
WO/2017/027973A1
The present disclosure provides for compounds useful for the treatment or prevention of disorders with an etiology associated with or comprising excessive cytokine or chemokine release. The compounds are also useful for the treatment of ...  
WO/2017/027136A2
The present invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected from the group of Apigenin, Cannflavin A, Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside, Kaemp...  
WO/2017/024980A1
Disclosed is a crystallization separation method for a nebivolol hydrochloride intermediate mixture, which comprises the following steps: step 1, adding an alcohol solvent or a mixed solvent of an alcohol and an alkane to a nebivolol hyd...  
WO/2017/023124A1
The present invention relates to a novel method for preparing a chromanol derivative. According to the present invention, unlike a conventionally known optically active reduction technique, a method for preparing a chromanol derivative h...  
WO/2017/020125A1
The present application is directed to transdermal formulations comprising one or more capsaicinoinds, one or more 1,4-dialdehyde sesquiterpenes, a penetration enhancer comprising tetrahydropiperine and a transdermal formulation base. Th...  
WO/2016/192829A8
The present invention relates to feed media comprising deep eutectic solvents and/or ionic liquids.  
WO/2017/017048A1
N-(2-oxaadamantan-1-yl)ureas of formula I, where R3 is H, C1-C3 alkyl, cyclohexyl or phenyl; R is -[CH2]n -Y; n is 0-15; in -[CH2]n - 0-n/3 of the methylene groups are optionally replaced by non adjacent oxygen atoms; and Y is a 3- or 4-...  
WO/2017/018847A1
The present invention relates to a composition for inhibiting the formation of a snare complex, containing myricetin derivatives, and can provide a composition for inhibiting the formation of a snare complex, in which myricetin derivativ...  
WO/2017/015221A1
Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseas...  
WO/2017/014285A1
A (meth)acryloyl compound represented by formula (A). (In formula (A): X is a single bond or a C1-60 2m-valent group; Z independently represents an oxygen atom, a sulfur atom, or being non-crosslinked; R1 independently represents a linea...  
WO/2017/013299A1
The invention relates to a method for producing a concentrate of polymer proanthocyanidins with a concentration of more than 40%, characterised by the use of enzymatic treatments and by the absence of organic solvents and/or the extracti...  
WO2017010381A1
Provided is an N-terminal labeling agent for a protein, comprising a compound represented by general formula (1) (where F is a fluorescent group, and R is an optionally substituted linker group having a linear soft segment formed from a ...  
WO/2017/011210A1
The present disclosure relates to the preparation of a cannabidiol compound or a derivative thereof. The cannabidiol compound or derivatives thereof can be prepared by an acid-catalyzed reaction of a suitably selected and substituted di-...  
WO/2012/025587A9
The present invention is directed to a process for the manufacture of 2,3,5-trimethyl-hydro-p-benzoquinone comprising the following steps: a) hydrogenating 2,6-dimethyl-p-benzoquinone with hydrogen in the presence of a hydrogenation cata...  
WO/2016/209753A1
Described herein are compounds, methods, and kits for short- and long-term tracking of cell proliferation, differentiation, and/or function. The compounds disclosed herein are coumarin- based cell-tracking reagents that fluoresce in the ...  
WO/2016/208866A1
The present invention relates to a polymer compound used as a coloring resin composition for a color filter, the polymer compound including a structure represented by [chemical formula 1] or [chemical formula 2], and having excellent hea...  
WO/2016/207913A1
The present disclosure provides a composition comprising brazilein which can be used as a fluorescent dye for enhanced visualization of nucleic acids such as DNA, and RNA. Also provided in the specification is a simple, time and cost eff...  
WO/2016/205923A1
There is disclosed a process for forming an ingestible therapeutic plant source pill. In an embodiment, the process comprises: decarboxylating the plant source material to release carbon dioxide; testing potency of the plant source mater...  
WO/2016/210392A1
N-substituted hydroxamic acids with carbon-based leaving groups as efficient HNO donors are disclosed. Pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions als...  
WO/2016/201536A1
The present invention relates to a biotransformation method for transforming phenolic compounds from soy milk into bioactive isoflavones and equol, with a high yield and production volume, for use in the biotechnological field, mainly in...  
WO/2016/204570A1
Provided in the present specification are a xanthene-based compound having a novel structure and a light-sensitive resin composition comprising same, and a light-sensitive material, a colour filter and a display element produced using same.  
WO/2016/197463A1
Disclosed are a formononetin aliphatic ether derivative, and a preparation method and a pharmaceutical use thereof. Particularly disclosed are a formononetin aliphatic ether derivative of general formula (I), the preparation method there...  
WO/2016/200934A1
Compounds, compositions and methods useful for treating cancer and neiirodegeneration are provided. The compounds comprise a mitochondria-targeting moiety linked to β-lapachone or a β-lapachone derivative.  
WO/2016/191872A1
Methods and compositions are provided for the treatment of familial exudative vitreoretinopathy (FEVR) through the administration of a therapeutically effective amount of a sphingosine-1-phosphate receptor type 2 (S1PR2) antagonist. Also...  
WO/2016/193220A1
The present invention relates to a method for changing the pigmentation of a skin, a mucous membrane or hair with a compound of general formula (I), a cosmetic use of said compound of general formula (I), to cosmetic compositions compris...  
WO/2016/192829A1
The present invention relates to feed media comprising deep eutectic solvents and/or ionic liquids.  
WO/2016/192830A1
The present invention relates to cell culture media compositions comprising deep eutectic solvents and/or ionic liquids.  
WO/2016/192631A1
The present invention provides an abietane-type diterpene compound having lipid-lowering activity, a method for preparing same, and use of same. Specifically, the compound has the structure shown in formula I. The definitions of the grou...  
WO/2016/189877A1
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the...  
WO/2016/168670A3
The present disclosure relates to methods of extending the lifespan of a subject or treating, suppressing, inhibiting or delaying the onset of an age-related condition or disorder, such as cancer, in a subject. The methods comprise admin...  
WO/2016/187722A1
Ocular compositions comprising a CB2 target agent and a cannabimimetic agent that is a non-selective cannabinoid receptor agent are useful in the treatment of ocular inflammation and ocular neuropathic pain. The CB2 target agent may be a...  
WO/2016/188945A1
The present invention relates to the field of separating chiral isomers from each other. Particularly, it relates to the field of separating of chiral isomers of chromane or chromene compounds, particularly tocopherols, 3,4-dehydro-tocop...  
WO/2016/126423A3
Z is CR4R5, C=CR4R5 SiR4R5, GeR4R5 NR4a, PR4a, P(O)R4a, O, S, SO, SO2, Se; SeO, SeO2, Te, TeO, or TeO2; R1 - R3 are the same or different at each occurrence and are D, aryl, heteroaryl, alkyl, amino, silyl, germyl, deuterated aryl, deute...  
WO/2016/190852A1
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of chromanyl compounds, and/or naturally or artificially occurring derivatives, analogues, stereoisomer...  
WO/2016/183809A1
The present invention relates to a nebivolol synthesis method and intermediate compound thereof. Specifically, the present invention relates to a method for synthesizing nebivolol, intermediate compound thereof and method for preparing t...  
WO/2016/183157A1
Isoflavonoids or pharmaceutically acceptable salts thereof or pharmaceutically acceptable compositions thereof for the treatment of prostate cancer or for the treatment or inhibition of prostate cancer metastasis in a patient in need the...  
WO/2016/183185A1
Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I): including stereoisomers, salts and tautomers thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, L4, M, m and n are as defined he...  
WO/2016/179645A1
The present disclosure relates to 4H-pyran compounds of formula (I) and their use in therapy, to compositions and agents comprising said compounds, to methods of treatment using said compounds, and their use in the manufacture of medicam...  
WO/2016/183315A1
A glutathione-cleavable prodrug is provided herein, as well as methods for its use in treating cancer, including triple negative breast cancer. The prodrug can be cleaved by glutathione under physiological conditions to generate a biolog...  
WO/2016/100576A9
The invention relates to methods of separating Trolox isomers (R)-Trolox and (S)-Trolox, comprising: (a) contacting a mixture of (R) and (S)-Trolox with a resolving agent selected from the group consisting of (1S,2S)-(+)-Pseudoephedrine,...  
WO/2016/174226A1
The present invention relates to compounds of general formula (I), wherein R1-R8 take various meanings, pharmaceutical compositions containing them and their use in medicine, particularly for the treatment and/or prophylaxis of cancer.  

Matches 651 - 700 out of 15,200